The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
The making of bispecific antibodies
Open accessAbstract
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG structure, and large complex molecules composed of different antigen-binding moieties often combined with dimerization modules. The application of sophisticated molecular design and genetic engineering has solved many of the technical problems associated with the formation of bispecific antibodies such as stability, solubility and other parameters that confer drug properties. These parameters may be summarized under the term 'developability'. In addition, different 'target product profiles', i.e., desired features of the bispecific antibody to be generated, mandates the need for access to a diverse panel of formats. These may vary in size, arrangement, valencies, flexibility and geometry of their binding modules, as well as in their distribution and pharmacokinetic properties. There is not 'one best format' for generating bispecific antibodies, and no single format is suitable for all, or even most of, the desired applications. Instead, the bispecific formats collectively serve as a valuable source of diversity that can be applied to the development of therapeutics for various indications. Here, a comprehensive overview of the different bispecific antibody formats is provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
scFv Antibody: Principles and Clinical Application
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/980250 · Cited by 760
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
Self-citationStrategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Self-citationHybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 517
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Self-citationVariants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Blinatumomab: A historical perspective
Nagorsen, D., Kufer, P., Baeuerle, P. A., & Bargou, R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.013 · Cited by 355
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351 · cited 1×
“, to crosslink to cell surfacedisplayed antigens.(41)”
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1696 · Cited by 345
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
New protein engineering approaches to multivalent and bispecific antibody fragments
Plückthun, A., & Pack, P. (1997) · Immunotechnology · doi:10.1016/s1380-2933(97)00067-5 · Cited by 322
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Alt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0820 · Cited by 278
Recombination of a mixture of univalent antibody fragments of different specificity
Nisonoff, A., & Rivers, M. M. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90296-x · Cited by 277
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
DiGiandomenico, A., Keller, A. E., Gao, C., Rainey, G. J., Warrener, P., Camara, M. M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009655 · Cited by 277
Stable, soluble T-cell receptor molecules for crystallization and therapeutics
Boulter, J. M., Glick, M., Todorov, P. T., Baston, E., Sami, M., Rizkallah, P., & Jakobsen, B. K. (2003) · Protein Engineering Design and Selection · doi:10.1093/protein/gzg087 · Cited by 276
Atwell, S., Ridgway, J. B. B., Wells, J. A., & Carter, P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1116 · Cited by 261
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Brennan, M., Davison, P. F., & Paulus, H. (1985) · Science · doi:10.1126/science.3925553 · Cited by 251
Tiller, K. E., & Tessier, P. M. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071114-040733 · Cited by 251
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.-Y., Nishimura, M., Greve, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302725110 · Cited by 236
Design and production of novel tetravalent bispecific antibodies
Coloma, M. J., & Morrison, S. L. (1997) · Nature Biotechnology · doi:10.1038/nbt0297-159 · Cited by 236
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 235
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Lewis, S. M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H. L., Guntas, G., Leaver-Fay, A., Smith, E. M., Ho, C., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2797 · Cited by 234
A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B., & Pastan, I. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7538 · Cited by 223
Self-citationMüller, D., Karle, A., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700820200 · Cited by 222
Self-citationHigh avidity scFv multimers; diabodies and triabodies
Hudson, P. J., & Kortt, A. A. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00157-x · Cited by 219
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 2×
“Preferential pairing of light chains with its corresponding heavy chain was described.(141) Importantly, the heteromeric Fc part allows fractionated purification by protein A chromatography”
BackgroundMethodRossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209
Formation of a bispecific antibody by the use of leucine zippers
Kostelny, S. A., Cole, M. S., & Tso, J. Y. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1547 · Cited by 207
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Klein, C., Sustmann, C., Thomas, M., Stubenrauch, K., Croasdale, R., Schanzer, J., Brinkmann, U., Kettenberger, H., Regula, J. T., & Schaefer, W. (2012) · mAbs · doi:10.4161/mabs.21379 · Cited by 201
Self-citationEngineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Huang, Y., Yu, J., Lanzi, A., Yao, X., Andrews, C. D., Tsai, L., Gajjar, M. R., Sun, M., Seaman, M. S., Padte, N. N., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.024 · Cited by 199
Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.001 · Cited by 198
Spiess, C., Merchant, M., Huang, A., Zheng, Z., Yang, N.-Y., Peng, J., Ellerman, D., Shatz, W., Reilly, D., Yansura, D. G., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2621 · Cited by 197
Structural characterization of a human Fc fragment engineered for lack of effector functions
Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall'Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 197
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities
Armour, K. L., Clark, M. R., Hadley, A. G., & Williamson, L. M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j · Cited by 192
Design of multivalent complexes using the barnase·barstar module
Deyev, S. M., Waibel, R., Lebedenko, E. N., Schubiger, A. P., & Plückthun, A. (2003) · Nature Biotechnology · doi:10.1038/nbt916 · Cited by 191
Crystal structure of a diabody, a bivalent antibody fragment
Perisic, O., Webb, P. A., Holliger, P., Winter, G., & Williams, R. L. (1994) · Structure · doi:10.1016/s0969-2126(94)00123-5 · Cited by 189
Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 188
Single-domain antibodies as building blocks for novel therapeutics
SAERENS, D., GHASSABEH, G., & MUYLDERMANS, S. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.006 · Cited by 186
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Klein, C., Schaefer, W., & Regula, J. T. (2016) · mAbs · doi:10.1080/19420862.2016.1197457 · Cited by 185
Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E., ‘t Hart, B., Poelmans, S., Bontinck, L., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0651-0 · Cited by 180
Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli, V., Bassi, R., Anselma, D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500815200 · Cited by 180
Bispecific human IgG by design
Carter, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00339-2 · Cited by 167
Smith, E. J., Olson, K., Haber, L. J., Varghese, B., Duramad, P., Tustian, A. D., Oyejide, A., Kirshner, J. R., Canova, L., Menon, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17943 · Cited by 167
Haberger, M., Bomans, K., Diepold, K., Hook, M., Gassner, J., Schlothauer, T., Zwick, A., Spick, C., Kepert, J. F., Hienz, B., et al. (2014) · mAbs · doi:10.4161/mabs.27876 · Cited by 162
Reusch, U., Burkhardt, C., Fucek, I., Le Gall, F., Le Gall, M., Hoffmann, K., Knackmuss, S. H., Kiprijanov, S., Little, M., & Zhukovsky, E. A. (2014) · mAbs · doi:10.4161/mabs.28591 · Cited by 161
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Junttila, T. T., Li, J., Johnston, J., Hristopoulos, M. L., Clark, R. A., Ellerman, D. A., Wang, B.-E., Li, Y., Mathieu, M. A., Li, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3622-t · Cited by 161
[17] Bispecific monoclonal antibodies from hybrid hybridomas
Suresh, M. R., Cuello, A. C., & Milstein, C. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)21019-8 · Cited by 160
Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 160
A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
Byrne, H., Conroy, P. J., Whisstock, J. C., & O’Kennedy, R. J. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.08.007 · Cited by 159
A revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157
Single chain Fab (scFab) fragment
Hust, M., Jostock, T., Menzel, C., Voedisch, B., Mohr, A., Brenneis, M., Kirsch, M. I., Meier, D., & Dübel, S. (2007) · BMC Biotechnology · doi:10.1186/1472-6750-7-14 · Cited by 156
Wines, B. D., Powell, M. S., Parren, P. W. H. I., Barnes, N. C., & Hogarth, P. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5313 · Cited by 152
Improving target cell specificity using a novel monovalent bispecific IgG design
Mazor, Y., Oganesyan, V., Yang, C., Hansen, A. M., Wang, J., Liu, H., Sachsenmeier, K. F., Marcia, C., Gadre, D., Borrok, M. J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007816 · Cited by 152
Structural and functional characterization of the trifunctional antibody catumaxomab
Chelius, D., Ruf, P., Gruber, P., Plöscher, M., Liedtke, R., Gansberger, E., Heß, J., Wasiliu, M., & Lindhofer, H. (2010) · mAbs · doi:10.4161/mabs.2.3.11791 · Cited by 152
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
Labrijn, A. F., Meesters, J. I., Priem, P., de Jong, R. N., van den Bremer, E. T. J., van Kampen, M. D., Gerritsen, A. F., Schuurman, J., & Parren, P. W. H. I. (2014) · Nature Protocols · doi:10.1038/nprot.2014.169 · Cited by 150
Piccione, E. C., Juárez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., & Majeti, R. (2015) · mAbs · doi:10.1080/19420862.2015.1062192 · Cited by 148
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Strop, P., Ho, W.-H., Boustany, L. M., Abdiche, Y. N., Lindquist, K. C., Farias, S., Rickert, M., Appah, C. T., Pascua, E., Radcliffe, T., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.04.020 · Cited by 148
Recombinant bispecific antibodies for cancer therapy
Kontermann, R. E. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00008.x · Cited by 142
Self-citationBrünker, P., Wartha, K., Friess, T., Grau-Richards, S., Waldhauer, I., Ferrara, C., Weiser, B., Majety, M., Runza, V., Niu, H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0647 · Cited by 142
Reiter, Y., Brinkmann, U., Lee, B., & Pastan, I. H. (1996) · Nature Biotechnology · doi:10.1038/nbt1096-1239 · Cited by 140
Self-citationStability engineering of scFvs for the development of bispecific and multivalent antibodies
Miller, B., Demarest, S. J., Lugovskoy, A. A., Huang, F., Wu, X., Snyder, W. B., Croner, L. J., Wang, N. C., Amatucci, A., Michaelson, J. S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq028 · Cited by 139
Kügler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., Schubert, I. A., Singer, H., Oduncu, F. S., Stockmeyer, B., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08300.x · Cited by 137
Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells
Sung, J., Pickeral, J., Liu, L., Stanfield-Oakley, S., Lam, C. K., Garrido, C., Pollara, J., LaBranche, C. C., Bonsignori, M., Moody, M. A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82314 · Cited by 137
Bispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137
Self-citationImmunotherapeutic perspective for bispecific antibodies
van Spriel, A. B., van Ojik, H. H., & van de Winkel, J. G. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01659-5 · Cited by 133
Tustian, A. D., Endicott, C. E., Adams, B., Mattila, J., & Bak, H. (2016) · mAbs · doi:10.1080/19420862.2016.1160192 · Cited by 129
Le Gall, F., Kipriyanov, S. M., Moldenhauer, G., & Little, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00713-9 · Cited by 128
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Wozniak‐Knopp, G., Bartl, S., Bauer, A., Mostageer, M., Woisetschläger, M., Antes, B., Ettl, K., Kainer, M. A., Weberhofer, G., Wiederkum, S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq005 · Cited by 126
Chemical generation of bispecific antibodies
Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., van Hagen, C., Levin, N. J., Shields, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016478108 · Cited by 124
Lu, D., Zhang, H., Ludwig, D. L., Persaud, A., Jimenez, X., Burtrum, D. B., Balderes, P. J., Liu, M., Böhlen, P., Witte, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310132200 · Cited by 124
Improving biophysical properties of a bispecific antibody scaffold to aid developability
von Kreudenstein, T. S., Escobar-Cabrera, E., Lario, P. I., D’Angelo, I., Brault, K., Kelly, J. F., Durocher, Y., Baardsnes, J., Woods, R. J., Xie, M. H., et al. (2013) · mAbs · doi:10.4161/mabs.25632 · Cited by 123
Bispecific antibodies rise again
Garber, K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4478 · Cited by 122
Construction, expression, and activity of a bivalent bispecific single-chain antibody.
Mallender, W. D., & Voss, E. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42334-9 · Cited by 120
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., Gueneau, F., Ravn, U., Depoisier, J.-F., Moine, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms7113 · Cited by 120
Boado, R. J., Zhou, Q.-H., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900235k · Cited by 117
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
Unverdorben, F., Richter, F., Hutt, M., Seifert, O., Malinge, P., Fischer, N., & Kontermann, R. E. (2015) · mAbs · doi:10.1080/19420862.2015.1113360 · Cited by 117
Self-citationMichaelson, J. S., Demarest, S. J., Miller, B., Amatucci, A., Snyder, W. B., Wu, X., Huang, F., Phan, S., Gao, S. X., Doern, A., et al. (2009) · mAbs · doi:10.4161/mabs.1.2.7631 · Cited by 116
Bernardis, F. D., Liu, H., O’Mahony, R., Valle, R. L., Bartollino, S., Sandini, S., Grant, S., Brewis, N., Tomlinson, I. M., Basset, R. C., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509891 · Cited by 114
Schmohl, J., Gleason, M., Dougherty, P., Miller, J. S., & Vallera, D. A. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0391-8 · Cited by 112
Moore, G. L., Bautista, C., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Eivazi, A., Muchhal, U. S., Karki, S., Chu, S. Y., & Lazar, G. A. (2011) · mAbs · doi:10.4161/mabs.3.6.18123 · Cited by 110
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 110
Yang, Z., Schmidt, D., Liu, W., Li, S., Shi, L., Sheng, J., Chen, K., Yu, H., Tremblay, J. M., Chen, X., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu196 · Cited by 107
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Riethmüller, G. (2012) · Europe PMC (PubMed Central) · Cited by 107
IgG2m4, an engineered antibody isotype with reduced Fc function
An, Z., Forrest, G., Moore, R., Cukan, M. C., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lü, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 104
Root, A. R., Cao, W., Li, B., LaPan, P., Meade, C., Sanford, J. D., Jin, M., O’Sullivan, C., Cummins, E., Lambert, M. A., et al. (2016) · Antibodies · doi:10.3390/antib5010006 · Cited by 103
A modular IgG-scFv bispecific antibody topology
Orcutt, K. D., Ackerman, M. E., Cieslewicz, M., Quiroz, E., Slusarczyk, A. L., Frangioni, J. V., & Wittrup, K. D. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp077 · Cited by 102
Vallera, D. A., Todhunter, D. A., Kuroki, D. W., Shu, Y., Sicheneder, A., & Chen, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2290 · Cited by 99
Gruber, M., Schodin, B. A., Wilson, E. R., & Kranz, D. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.11.5368 · Cited by 98
Silacci, M., Lembke, W., Woods, R., Attinger-Toller, I., Bänziger-Tobler, N. E., Batey, S., Santimaria, R., von der Bey, U., Koenig-Friedrich, S., Zha, W., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1093266 · Cited by 95
Wu, C., Hua, Y., Bose, S., Miller, R., Medina, L., Santora, L. C., & Ghayur, T. (2009) · mAbs · doi:10.4161/mabs.1.4.8755 · Cited by 94
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
Holliger, P., Brissinck, J., Williams, R. L., Thielemans, K., & Winter, G. P. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.3.299 · Cited by 94
de Kruif, J., & Logtenberg, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7630 · Cited by 93
Dimasi, N., Gao, C., Fleming, R. L., Woods, R. M., Yao, X.-T., Shirinian, L., Kiener, P. A., & Wu, H. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.032 · Cited by 92
Shatz-Binder, W., Chung, S., Li, B., Marshall, B., Tejada, M. L., Phung, W., Sandoval, W. N., Kelley, R. F., & Scheer, J. M. (2013) · mAbs · doi:10.4161/mabs.26307 · Cited by 92
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Schuhmacher, J., Benner, A., Moldenhauer, G., & Little, M. (2000) · PubMed · Cited by 91
Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
Xu, Y.-R., Lee, J., Tran, C., Heibeck, T. H., Wang, W. D., Yang, J.-H., Stafford, R., Steiner, A. R., Sato, A., Hallam, T., et al. (2014) · mAbs · doi:10.4161/19420862.2015.989013 · Cited by 91
Gramer, M. J., van den Bremer, E. T. J., van Kampen, M. D., Kundu, A., Kopfmann, P., Etter, E., Stinehelfer, D., Long, J., Lannom, T., Noordergraaf, E. H., et al. (2013) · mAbs · doi:10.4161/mabs.26233 · Cited by 91
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91
Bispecific antibody platforms for cancer immunotherapy
Lameris, R., de Bruin, R. C. G., Schneiders, F. L., Henegouwen, P. M. P. V. B. E., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.003 · Cited by 90
ImmTACs for targeted cancer therapy: Why, what, how, and which
Oates, J., Hassan, N. J., & Jakobsen, B. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.024 · Cited by 90
Reusch, U., Harrington, K. H., Gudgeon, C. J., Fucek, I., Ellwanger, K., Weichel, M., Knackmuss, S. H. J., Zhukovsky, E. A., Fox, J. A., Kunkel, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0350 · Cited by 90
Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.004 · Cited by 89
Self-citationRemodeling domain interfaces to enhance heterodimer formation
Zhu, Z., Presta, L. G., Zapata, G. A., & Carter, P. M. (1997) · Protein Science · doi:10.1002/pro.5560060404 · Cited by 87
Gall, F. L., Reusch, U., Little, M., & Kipriyanov, S. M. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh039 · Cited by 86
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 86
Insights into the molecular basis of a bispecific antibody's target selectivity
Mazor, Y., Hansen, A. M., Yang, C., Chowdhury, P. S., Wang, J., Stephens, G. L., Wu, H., & Dall’Acqua, W. F. (2015) · mAbs · doi:10.1080/19420862.2015.1022695 · Cited by 85
Razinkov, V. I., Treuheit, M. J., & Becker, G. W. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114565593 · Cited by 85
A review of blinatumomab, a novel immunotherapy
Newman, M. J., & Benani, D. J. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215618770 · Cited by 84
Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K., & Hassan, N. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1525-z · Cited by 81
Rozan, C., Cornillon, A., Pétiard, C., Chartier, M., Béhar, G., Boix, C., Kerfélec, B., Robert, B., Pèlegrin, A., Chames, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1012 · Cited by 81
Hu, S., Fu, W., Xu, W., Yang, Y., Cruz, M., Berezov, S. D., Jorissen, D., Takeda, H., & Zhu, W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1670 · Cited by 81
Dong, J., Sereno, A., Aivazian, D., Langley, E. J., Miller, B., Snyder, W. B., Chan, E., Cantele, M., Morena, R., Joseph, I. B. J., et al. (2011) · mAbs · doi:10.4161/mabs.3.3.15188 · Cited by 80
Liu, Z., Leng, E. C., Gunasekaran, K., Pentony, M., Shen, M., Howard, M., Stoops, J. D., Manchulenko, K., Razinkov, V. I., Liu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620260 · Cited by 78
Boström, J., Haber, L., Koenig, P. S., Kelley, R. F., & Fuh, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017887 · Cited by 78
Kellner, C., Bruenke, J., Stieglmaier, J., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318186c8b4 · Cited by 78
Müller, K. M., Arndt, K. M., Strittmatter, W., & Plückthun, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00021-0 · Cited by 78
Alt, M., Müller, R., & Kontermann, R. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00782-6 · Cited by 77
Self-citationSharkey, R. M., Rossi, E. A., McBride, W. J., Chang, C., & Goldenberg, D. M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.002 · Cited by 77
Engineering and Pharmacology of Blood–Brain Barrier-Permeable Bispecific Antibodies
Stanimirovic, D. B., Kemmerich, K., Haqqani, A. S., & Farrington, G. K. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.005 · Cited by 77
A dimeric bispecific miniantibody combines two specificities with avidity
Müller, K. M., Arndt, K. M., & Plückthun, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00829-1 · Cited by 76
Sharkey, R. M., Karacay, H., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C.-H., & Goldenberg, D. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0037 · Cited by 75
The emerging role of new protein scaffold-based agents for treatment of cancer.
Weidle, U. H., Auer, J., Brinkmann, U., Georges, G. J., & Tiefenthaler, G. (2013) · PubMed · Cited by 74
Self-citationUtilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Stieglmaier, J., Benjamin, J., & Nagorsen, D. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1041373 · Cited by 73
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., & Chang, C. (2009) · Blood · doi:10.1182/blood-2008-10-187138 · Cited by 72
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
Jakob, C. G., Edalji, R. P., Judge, R. A., DiGiammarino, E. L., Li, Y., Gu, J., & Ghayur, T. (2013) · mAbs · doi:10.4161/mabs.23977 · Cited by 72
Spiess, C., Bevers, J. J., Jackman, J. K., Chiang, N., Nakamura, G. R., Dillon, M. A., Liu, H., Molina, P., Elliott, J. M., Shatz-Binder, W., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.480483 · Cited by 72
Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity
McCall, A. M., Shahied, L., Amoroso, A. R., Horak, E. M., Simmons, H. H., Nielson, U., Adams, G. P., Schier, R., Marks, J. D., & Weiner, L. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6112 · Cited by 72
Völkel, T., Korn, T., Bach, M., Müller, R., & Kontermann, R. E. (2001) · Protein Engineering Design and Selection · doi:10.1093/protein/14.10.815 · Cited by 71
Self-citationFab-based bispecific antibody formats with robust biophysical properties and biological activity
Wu, X., Sereno, A., Huang, F., Lewis, S. M., Lieu, R., Weldon, C. L., Torres, C., Fine, C., Batt, M. A., Fitchett, J. R., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1022694 · Cited by 68
Bispecific digoxigenin-binding antibodies for targeted payload delivery
Metz, S., Haas, A. K., Daub, K., Croasdale, R., Stracke, J. O., Lau, W., Georges, G. J., Josel, H., Dziadek, S., Hopfner, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018565108 · Cited by 68
Self-citationCloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing
Große‐Hovest, L., Müller, S., Minoia, R., Wolf, E., Zakhartchenko, V., Wenigerkind, H., Lassnig, C., Besenfelder, U., Müller, M. M., Lytton, S. D., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308487101 · Cited by 68
Schoonjans, R., Willems, A. V., Schoonooghe, S., Fiers, W. C., Grooten, J., & Mertens, N. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7050 · Cited by 67
Computationally Designed Bispecific Antibodies using Negative State Repertoires
Leaver‐Fay, A., Froning, K., Atwell, S., Aldaz, H., Pustilnik, A., Lu, F., Huang, F., Yuan, R. G., Hassanali, S., Chamberlain, A. K., et al. (2016) · Structure · doi:10.1016/j.str.2016.02.013 · Cited by 66
World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
Dhimolea, E., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.4.1.18821 · Cited by 64
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Mabry, R., Lewis, K. E., Moore, M. D., McKernan, P. A., Bukowski, T. R., Bontadelli, K., Brender, T., Okada, S. L., Lum, K. D., West, J. W., et al. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp073 · Cited by 64
Steinmetz, A. C. U., Vallée, F., Beil, C., Lange, C. M., Baurin, N., Beninga, J., Capdevila, C., Corvey, C., Dupuy, A., Ferrari, P., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1162932 · Cited by 64
Cancer therapy with bispecific antibodies: Clinical experience.
Thakur, A. B., & Lum, L. G. (2010) · PubMed · Cited by 63
Lu, D., Jimenez, X., Witte, L., & Zhu, Z. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.060 · Cited by 63
Complement recruitment using bispecific diabodies
Kontermann, R. E., Wing, M. G., & Winter, G. P. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-629 · Cited by 63
Self-citationSchanzer, J., Jekle, A., Nezu, J., Lochner, A., Croasdale, R., Dioszegi, M., Zhang, J., Hoffmann, E., Dormeyer, W., Stracke, J. O., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00215-10 · Cited by 62
Self-citationPardridge, W. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1230195 · Cited by 61
Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers
Dall’Acqua, W. F., Simon, A. L., Mulkerrin, M. G., & Carter, P. M. (1998) · Biochemistry · doi:10.1021/bi980270i · Cited by 60
Schanzer, J. M., Wartha, K., Croasdale, R., Moser, S., Künkele, K., Ries, C. H., Scheuer, W., Dürr, H., Pompiati, S., Pollman, J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.528109 · Cited by 60
Self-citationBrandão, J. G., Scheper, R. J., Lougheed, S. M., Curiel, D. T., Tillman, B. W., Gerritsen, W. R., van den Eertwegh, A. J. M., Pinedo, H. M., Haisma, H. J., & de Gruijl, T. D. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00050-1 · Cited by 60
Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2412 · Cited by 59
Lacy, S. E., Wu, C., Ambrosi, D. J., Hsieh, C.-M., Bose, S., Miller, R., Conlon, D., Tarcsa, E., Chari, R. V. J., Ghayur, T., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1026501 · Cited by 58
Qu, Z., Goldenberg, D. M., Cardillo, T. M., Shi, V., Hansen, H. J., & Chang, C. (2007) · Blood · doi:10.1182/blood-2007-08-110072 · Cited by 58
Schubert, I. A., Kellner, C., Stein, C., Kügler, M., Schwenkert, M., Saul, D., Mentz, K., Singer, H., Stockmeyer, B., Hillen, W., et al. (2011) · mAbs · doi:10.4161/mabs.3.1.14057 · Cited by 58
Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies
Kipriyanov, S. M., Moldenhauer, G., Braunagel, M., Reusch, U., Cochlovius, B., Gall, F. L., Kouprianova, O. A., von der Lieth, C., & Little, M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00526-6 · Cited by 58
Choi, H., Kim, Y., Lee, S., & Kim, Y. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0628 · Cited by 58
Kanakaraj, P., Puffer, B. A., Yao, X.-T., Kankanala, S., Boyd, E., Shah, R. R., Wang, G., Patel, D., Krishnamurthy, R., Kaithamana, S., et al. (2012) · mAbs · doi:10.4161/mabs.21227 · Cited by 57
Asano, R., Watanabe, Y., Kawaguchi, H., Fukazawa, H., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704719200 · Cited by 56
Muda, M., Gross, A. W., Dawson, J., He, C., Kurosawa, E., Schweickhardt, R. L., Dugas, M., Soloviev, M., Bernhardt, A., Fischer, D., et al. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq123 · Cited by 55
Design, Construction, and In Vitro Analyses of Multivalent Antibodies
Miller, K. F., Meng, G., Liu, J., Hurst, A., Hsei, V., Wong, W. L., Ekert, R., Lawrence, D. A., Sherwood, S. W., DeForge, L. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4854 · Cited by 54
Hayden, M. S., Linsley, P. S., Gayle, M. A., Bajorath, J., Brady, W., Norris, N. A., Fell, H. P., Ledbetter, J. A., & Gilliland, L. K. (1994) · PubMed · Cited by 53
An Improved Single-Chain Fab Platform for Efficient Display and Recombinant Expression
Koerber, J. T., Hornsby, M. J., & Wells, J. A. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.11.017 · Cited by 53
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.
Rossi, E. A., Sharkey, R. M., McBride, W., Karacay, H., Li, Z., Hansen, H. J., Goldenberg, D. M., & Chang, C. (2003) · PubMed · Cited by 52
Rossi, E. A., Goldenberg, D. M., & Chang, C. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2004999 · Cited by 52
Dashivets, T., Stracke, J. O., Dengl, S., Knaupp, A., Pollmann, J., Büchner, J., & Schlothauer, T. (2016) · mAbs · doi:10.1080/19420862.2016.1231277 · Cited by 52
Kufer, P., Mack, M., Gruber, R., Lutterbüse, R., Zettl, F., & Riethmüller, G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050431 · Cited by 51
Dimerisation strategies for shark IgNAR single domain antibody fragments
Simmons, D. P., Abregu, F. A., Krishnan, U. V., Proll, D. F., Streltsov, V. A., Doughty, L., Hattarki, M. K., & Nuttall, S. D. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.07.019 · Cited by 51
Rossi, E. A., Chang, C., Losman, M. J., Sharkey, R. M., Karacay, H., McBride, W., Cardillo, T. M., Hansen, H. J., Qu, Z., Horak, I. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0020 · Cited by 50
LaFleur, D. W., Abramyan, D., Kanakaraj, P., Smith, R. G., Shah, R. R., Wang, G., Yao, X.-T., Kankanala, S., Boyd, E., Zaritskaya, L., et al. (2013) · mAbs · doi:10.4161/mabs.23043 · Cited by 50
Engineered IgG1‐Fc – one fragment to bind them all
Laurent, E., Traxlmayr, M. W., Obinger, C., & Hasenhindl, C. (2016) · Immunological Reviews · doi:10.1111/imr.12385 · Cited by 50
Single Variable Domain-IgG Fusion
Shen, J., Vil, M. D., Jimenez, X., Iacolina, M. D., Zhang, H., & Zhu, Z. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513415200 · Cited by 49
Gupta, P., Goldenberg, D. M., Rossi, E. A., Cardillo, T. M., Byrd, J. C., Muthusamy, N., Furman, R. R., & Chang, C. (2012) · Blood · doi:10.1182/blood-2011-09-381988 · Cited by 48
Expression of a bispecific dsFv–dsFv′ antibody fragment in Escherichia coli
Schmiedl, A., Breitling, F., & Dübel, S. (2000) · Protein Engineering Design and Selection · doi:10.1093/protein/13.10.725 · Cited by 48
Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
Croasdale, R., Wartha, K., Schanzer, J. M., Kuenkele, K. P., Ries, C. H., Mayer, K., Gassner, C., Wagner, M., Dimoudis, N., Herter, S., et al. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.016 · Cited by 48
Self-citationKellner, C., Bruenke, J., Horner, H., Schubert, J. E. A., Schwenkert, M., Mentz, K., Barbin, K., Stein, C., Peipp, M., & Stockmeyer, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.020 · Cited by 47
Wu, S.-C., Chen, Y.-J., Wang, H.-C., Chou, M.-Y., Chang, T., Yuan, S. F., Chen, C.-Y., Hou, M., Hsu, J. T.-A., & Wang, Y. (2015) · Theranostics · doi:10.7150/thno.13069 · Cited by 45
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
T cell-engaging therapies — BiTEs and beyond
Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 644
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Dimerization of two nanobodies or scFvs can also be achieved by genetic fusion to natural or synthetic dimerization domains (56).”
Background
Metadata
- Authors
- Brinkmann, U., & Kontermann, R. E.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2017-01-10
- Volume
- 9
- Issue
- 2
- Pages
- 182-212
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2571138221
- Cited by
- 923
- References
- 268
- FWCI
- 58.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.